Chaperones as potential therapeutics for Krabbe disease

Area of Science:

• Neurodegenerative Disorders
• Lysosomal Storage Diseases (LSDs)

Background:

• Krabbe disease (KD) is an autosomal recessive neurodegenerative disorder classified as a lysosomal storage disease (LSD).
• The genetic defect for the galactocerebrosidase (GALC) gene was identified in the 1970s, with GALC crystal structures obtained in 2011.
• Research into therapeutic interventions for KD, particularly pharmacological chaperone therapy (PCT), is relatively recent compared to other LSDs.

Purpose of the Study:

• To review potential therapeutic chaperones for Krabbe disease identified in preclinical studies.
• To highlight the need for increased research in KD-specific PCT.
• To emphasize the benefit of recent advancements in GALC structure, drug design, and cellular models for KD treatment development.

Main Methods:

• Review of preclinical studies on chaperones demonstrating therapeutic potential for Krabbe disease.
• Analysis of recent insights into GALC enzyme structure and function.
• Consideration of drug design and development in cellular models for KD.

Main Results:

• Pharmacological chaperone therapy (PCT) is a promising strategy for treating KD by correcting protein folding and enhancing enzyme activity.
• Several chaperones have shown potential in preclinical studies for KD.
• Current PCT research for KD is less advanced than for other LSDs.

Conclusions:

• Further research is crucial to invigorate the development of PCT for Krabbe disease.
• Recent molecular understanding of GALC structure and advancements in drug design can accelerate KD-targeted PCT.
• PCT holds significant promise as a therapeutic strategy for Krabbe disease.